Anne O'Dea, MD

Dr. Anne O'Dea is certified by the American Board of Internal Medicine with subcertification in hematology and medical oncology. She completed a fellowship at the University of Kansas Medical Center. She earned her medical degree from the University of Kansas School of Medicine and completed her residency at the University of Kansas Medical Center.

Clinical and Biomarker Results from Phase I/II Study of P13K Inhibitor Alpellsib Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer

Fixed dose, dose-dense capecitabine in metastatic breast cancer.

Impact of Germline BRCA Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer

Management of Metastatic Triple-Negative Breast Cancer

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

Pilot Feasibility Study Examining Pupillary Response During Driving Simulation as a Measure of Cognitive Load in Breast Cancer Survivors

Point of Care Genetic Testing in a Breast Cancer Survivorship Clinic

Pupillary response: cognitive effort for breast cancer survivors

Randomized Phase II Trial of Anthracycline-Free and Anthracycline-Containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-Negative Breast Cancer (NeoSTOP)

Reducing Breast Cancer-Related Lymphedema (BCRL) Through Prospective Surveillance Monitoring Using Bioimpedance Spectroscopy (BIS) and Patient Directed Self-Interventions.

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in state I-III triple-negative breast cancer

Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in state I-III triple-negative breast cancer

Safety and Efficacy Results From Phase I Study of BYL 719 Plus Nabpaclitaxel in HER2 Negative Metastatic Breast Cancer

Serial Single-Cell Genomics Reveals Convergent subclonal Evolution of Resistance as Patients with Early-Stage Breast Cancer Progress on Endocrine Plus CDK4/6 Therapy

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER2+ Breast Cancer, Phase III (S1501 Trial)

Carvedilol to Prevent Cardiac Dysfunction in Women with Metastatic Breast Cancer Taking HER-2 Targeted Therapy

Efficacy of Point of Service Testing- Breast Cancer (EPOST BC)

Efficacy of Point of Service Testing- Metastatic Breast Cancer (EPOST-MBC)

Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients with HR+ HER2- Advanced Breast Cancer

Elacestrant Monotherapy for the Treatment of Postmenopausal Women with ER+/HER2- Advanced Breast Cancer Following Cdk4/6 Inhibitor Therapy: A Phase III Randomized, Open-Label, Multicenter Trial (EMERALD)

KanSurvive: Testing Model for Improving Cancer Survivorship in Rural Practice

Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients with ER+ HER2- Primary Breast Cancer (the "Study")

PROspective Evaluation of Germline Mutations, Cancer Outcomes and Tissue Biomarkers (P.R.O.G.E.C.T.)

Randomized Phase II Trial of Fulvestrant or Exemestane With or Without Ribociclib After Progression on Anti-Estrogen Therapy Plus Cylin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (MAINTAIN Study)

Task Evoked Pupillary Response (TEPR): Cognitive Effort for Breast Cancer Survivors

The COMPASSHER2 (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2 Positive Breast Cancer) Residual Disease Trial, A Double-Blinded Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib

Understanding and Predicting Breast Cancer Events after Treatment (UPBEAT)